Liver International · 2003 · 15 citations · 24 references
PharmacyInternal MedicinePharmacotherapyHepatic PharmacotherapyHepatitis PharmacotherapyInfectious Disease PharmacotherapyAntiviral TherapyInterferon ResponsesInterferon-based TherapyTreatmentViral HepatitisViral Hepatitis TreatmentChronic Viral HepatitisInterferon Alfa TherapyRibavirin TherapyRibavirin-based RegimensType I Interferon InductionViral Kinetics
BACKGROUND/AIMS: Initial high-dose interferon-alpha induction therapy in combination with ribavirin improves sustained response rates in treatment-naïve patients. This prospective, randomized, controlled study tested whether non-responders or relapsers to interferon monotherapy also benefit from induction therapy. METHODS: Patients with chronic hepatitis C who had not responded to (n=75) or relapsed (n=80) after previous interferon therapy were randomized to receive three different interferon doses during the first 14 weeks of therapy (A: 10 MU IntronA/day for 2 weeks, followed by 10 MU/2 days for 12 weeks; B:5 MU/d for 14 weeks; C: 5 MU/2 days for 14 weeks) followed in all by 5 MU/2 days for 24 weeks. All patients received 1-1.2 g ribavirin/day throughout the whole study. RESULTS: The rates of viral clearance at any time on treatment were similar in all groups. Sustained response rates were also not different among the groups in interferon nonresponders (A 32%, B 29%, C 31%) and relapsers (A 64%, B 68%, C 71%), respectively, as well as in patients with different genotypes. As expected, sustained response rates were higher in patients with genotype non-1 than in those with genotype 1. CONCLUSION: High-dose induction therapy does not improve the outcome of interferon/ribavirin therapy in interferon nonresponders or relapsers.
24
Thierry Poynard, Patrick Marcellin, Samuel S. Lee et al. · The Lancet · 1998 · 2.3K citations
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
Avidan U. Neumann, Nancy P. Lam, Harel Dahari et al. · Science · 1998 · 2.1K citations